National
Health Ministry proposes immediate licence suspension for specified drug failures
Nyaya Prep • Published • 2 min read

India’s Union Health Ministry announced draft amendments to the Drugs Rules, 1945, on 4 November 2026. The proposed trigger is a Government Analyst’s report that declares a drug below standard on a specified critical quality measure. The relevant central or state licensing authority would then suspend the manufacturing licence for that drug immediately. The draft targets the delay that can occur when existing procedures require a show-cause notice before regulatory action.
The manufacturer would have to investigate the cause of the failure and implement measures to correct it and prevent it from happening again. The licensing authority would verify those steps before lifting the suspension. The draft also changes the circulation of the analyst’s Form 13 report so the national drug controller, the licensing authority for the manufacturing site, the manufacturer and the marketer receive it. These measures were put out for consultation.
Facts to remember
- Draft announced on 4 November 2026 by the Ministry of Health and Family Welfare.
- Specified quality measures: assay, dissolution, related substances, impurities and sterility.
- Form 13 is the Government Analyst’s test report; the draft proposes wider sharing of the findings.
- The public may submit feedback within 30 days from the date copies of the Gazette containing the draft become available.
Background
The Drugs and Cosmetics Act, 1940, supplies the statutory framework for drug quality and regulation. For the chapter dealing with manufacture, sale and distribution, Section 16 links the standard quality of a drug to the standards in the Second Schedule. The Drugs Rules, 1945, operate within that framework. The draft concerns the licensing response after a qualifying test result.
Why it matters for exams
For judiciary, APO and UGC-NET Law, revise delegated legislation, consultation and administrative licensing. CLAT candidates should remember what triggers the proposed suspension and what must happen before it is lifted.
- Drug quality
- Manufacturing licences
- Drugs Rules
- Public health
- Delegated legislation